New ISHLT nomenclature & diagnostic criteria: Antibody-mediated rejection in heart transplantation
(Elsevier Health Sciences) Antibody-mediated rejection of the transplanted heart is a recognized clinical complication and a major limitation to survival of patients who have undergone heart transplantation. Experts have now developed a new working formulation for the pathologic diagnosis, grading, and reporting of cardiac antibody-mediated rejection. Their consensus statement is published in the Dec. issue of The Journal of Heart and Lung Transplantation and is freely available online.
AbstractPurpose of the ReviewAlthough still a relatively new technology, long-term left ventricular assist devices (LVADs) for management of advanced heart failure is rapidly increasing. Initially designed as a bridge to transplant, these invasive devices are increasingly used as a destination therapy, creating unique and long-term infection risks. The aim of this comprehensive review is to highlight current evidence about the prevention, diagnosis, and management of LVAD-specific infections.Recent FindingsThere are two recent, major societal guidelines (The International Society for Heart and Lung Transplantation, 2017, a...
CONCLUSION: The future of organ bioengineering relies on furthering understanding of organogenesis, in vivo regeneration, regenerative immunology and long-term monitoring of implanted bioengineered organs. PMID: 32463143 [PubMed - in process]
We report a case of 2019-nCoV pneumonia with associated acute myocardial injury2 confirmed by biomarkers as well as cardiac Magnetic Resonance Imaging (MRI).
Publication date: Available online 27 May 2020Source: Respiratory Medicine Case ReportsAuthor(s): Lea Deterding, Tina Körner, Gudrun Borte, Hubert Wirtz, Hans-Jürgen Seyfarth
Of the four major solid organ transplants, median survival following lung transplantation (LTx) remains the shortest (5.7-5.8 years) with negligible improvements reported over the last decade due to high rates of chronic lung allograft dysfunction (CLAD), a progressive and ultimately fatal complication limiting long-term survival in transplantees.1 Bronchiolitis obliterans syndrome (BOS), often dubbed the “Achilles Heel” of lung transplantation, is the most common manifestation of CLAD and is resistant to most current treatment modalities, leaving repeat lung transplantation (re-LTx) the only treatment option.
Abstract Rescuing patients with the development of acute respiratory distress syndrome and right heart failure after left ventricular assist device placement remains a challenge in patients with congenital heart disease. TandemLife Protek Duo (TandemLife, Pittsburg, PA) is a double-lumen cannula introduced via the internal jugular vein that can provide veno-venous extra-corporeal membrane oxygenation and right heart support. To our knowledge, we report the first case of successfully using the TandemLife Protek Duo cannula to provide veno-venous extra-corporeal membrane oxygenation and right ventricle support in an...
Post-lung transplantation (post-LTx) progressive chronic kidney disease (CKD) is associated with increased morbidity and mortality.1 Comorbidities and cotreatments, and post-LTx medical complications, including acute kidney injury (AKI), are associated with an increased risk for subsequent CKD development.2 However, among the several risk factors for post-LTx CKD development, pre-transplant renal function plays a key role.3
Cardiac Cancer (CC) that arises from or involves the heart can present as heart failure, chest pain, stroke or another thromboembolic event. Although patients with CC have limited treatment options, in other organ cancers such as hepatocellular carcinoma, liver transplant improves 5-year overall survival in carefully selected patients1. For CC, however, the benefit of replacing the cancerous heart is uncertain because one-year survival is generally estimated around 50% after this rare operation.
Studies have shown that highly selected patients undergoing combined heart-kidney (HK) and heart-liver transplants (HLv) have short- and long-term outcomes comparable to those observed in primary heart transplantation (HT). Adults patients with stage D heart failure that underwent combined HK, HLv and heart-lung (HL) were identified in the United Network for Organ Sharing (UNOS) registry between 1991 and 2016, with follow-up through March 2018. We conducted inverse probability of treatment weighting (IPTW) survival analysis of long-term survival stratified by type of combined organ transplant, accounting for donor, recipie...
Over the past decade, the amount of patients with persistent opioid use after cardiac surgery has increased.1 The majority of cardiac surgical procedures, including left ventricular assist device (LVAD) implantation are associated with significant acute pain.2 The growing use of a multimodal analgesia approach utilizing opioid sparing regimen (OSR) techniques following surgery, has demonstrated effectiveness over the past two decades.3 Herein, we present our findings of our quality improvement initiative with a multimodal analgesia approach utilizing OSR in patients undergoing LVAD implantation.